Immunogenomic Correlates of Response to Cetuximab in Head and Neck Squamous Cell Carcinoma

Immune evasion is a sine qua non for cancer development. Mechanisms of resistance to immune modulating therapeutics in cancer are poorly understood. Less than 20% of patients with HNSCC have a lasting response to cetuximab. We hypothesized that acquired somatic alterations may provide a mechanism of immune evasion in cetuximab failure. Here, using a novel cohort of HNSCC patients treated with neoadjuvant cetuximab, we investigated mechanisms of immune escape from cetuximab therapy.

http://ift.tt/2ImO0E8